Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 7/20 | 0.67 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.67 |
| ▸ | PDGFRA | P16234 | 5/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6864433 | 0.91 | PDGFRB (0.67) | FLT3PDGFRBPDGFRAMEN1CYP1A2 | |
| SCHEMBL6867577 | 0.85 | FLT3 (0.63) | FLT3PDGFRBPDGFRAMEN1CYP1A2 | |
| SCHEMBL6865628 | 0.83 | PDGFRB (0.60) | FLT3PDGFRBPDGFRAMEN1CYP1A2 | |
| SCHEMBL6865103 | 0.81 | FLT3 (1.00) | FLT3PDGFRBPDGFRAMEN1CYP1A2 | |
| SCHEMBL6866887 | 0.79 | PDGFRB (1.00) | FLT3PDGFRBPDGFRAMEN1CYP1A2 | |
| SCHEMBL29354248 | 0.77 | MEN1 (1.00) | FLT3PDGFRBPDGFRAMEN1CYP1A2 | |
| SCHEMBL5828518 | 0.77 | MEN1 (1.00) | FLT3PDGFRBPDGFRAMEN1CYP1A2 | |
| SCHEMBL7066124 | 0.77 | FLT3 (0.72) | FLT3PDGFRBPDGFRAMEN1CYP1A2 | |
| SCHEMBL6866879 | 0.76 | PDGFRB (0.63) | FLT3PDGFRBPDGFRAMEN1CYP1A2 | |
| SCHEMBL6871064 | 0.74 | KDM4E (0.57) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6812243-B2 | AS TYROSINE KINASE INHIBITORS; FOR THERARPY OF TUMORS, ARTERIOSCLEROSIS, RESTENOSIS AFTER BALLOON ANGIOPLASTY, ARTHRITIS AND FIBROTIC DISEASES | ZENTARIS AG (DE) | 2004-11-02 | — | — | US | disclosed |
| US-20030008898-A1 | Indole derivatives and their use for the treatment of malignant and other diseases based on pathological proliferation | ZENTARIS AG (DE) | 2003-01-09 | — | — | US | disclosed |
| US-6407102-B1 | TYROSINE KINASE AND PLATELET-DERIVED GROWTH FACTOR INHIBITORS; ANTICARCINOGENIC, ANTITUMOR, ANTIARTHRITIC AND ANTIPROLIFERATIVE AGENTS; RESTENOSIS, ARTERIOSCLEROSIS | ZENTARIS AG (DE) | 2002-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008898-A1 | Indole derivatives and their use for the treatment of malignant and other diseases based on pathological proliferation | MKI67, IDO1, CCNI | FLT3 230/4885PDGFRB 474/4885PDGFRA 542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.